Article

No stimulant? No Problem: Analyzing Black Market Sales of Atomoxetine on StreetRx

2022-12-20

Abstract excerpt

<h4>Objective</h4> The purpose of this report was to analyze black market diversions of atomoxetine, a non-stimulant medication for ADHD, submitted to StreetRx. <h4>Method</h4> Data related to black market atomoxetine purchases entered on StreetRx between 2015 and 2019 were analyzed. Data included generic drug name, dosage, purchase price, and date and location in the United States. The mean price per milligram wa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 64d8ec51-8e38-5781-b106-0db4a3f0e0a5
DOI: 10.1101/2022.12.19.22283638

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

No stimulant? No Problem: Analyzing Black Market Sales of Atomoxetine on StreetRxDOI 10.1101/2022.12.19.22283638Read

Prevalence of stimulants among students of the Syrian Private University and its relationship with academic achievement and psychological stateSemantic proximity Read

Fentanyl, Heroin, and Methamphetamine-Based Counterfeit Pills Sold at Tourist-Oriented Pharmacies in Mexico: An Ethnographic and Drug Checking StudySemantic proximity Read

Increase in Rate of Hospitalizations for Pediatric Intentional Acetaminophen Ingestion at a Single Center During the COVID-19 PandemicSemantic proximity Read

Rise of escitalopram and the fall of citalopramSemantic proximity Read

Pronounced State Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019-2020)Semantic proximity Read

Can the neurodiversity approach apply to ADHD? Exploring the lived experience of ADHD as neurodivergenceSemantic proximity Read

Can the neurodiversity approach apply to ADHD? Exploring the lived experience of ADHD as neurodivergenceSemantic proximity Read

Shining a light in the black box of orphan drug pricingSemantic proximity Read

A Case of Excessive, Opportunistic Price Increase of a Generic Oncology DrugSemantic proximity Read

Does Medicaid Institutions for Mental Diseases Exclusion Waiver Crowd Out the Access to Treatment Among Commercially Insured Substance Use Disorder Patients? An Empirical Study Using Commercial Insurance Claims DataSemantic proximity Read

Pronounced Regional Variation in Esketamine and Ketamine Prescribing to US Medicaid PatientsSemantic proximity Read

Diverse Psychotropic Substances Detected in Drug and Paraphernalia Samples Submitted to Drug Checking Services in Toronto, Ontario, Canada, October 2019-April 2020Semantic proximity Read